Otonomy (OTIC) Investor Presentation - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Börse:
3,814€
-1,24%
Echtzeit-Aktienkurs Otonomy Inc.
Bid:
3,772€
Ask:
3,856€
Nachrichten zur Otonomy Inc. Aktie
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy: +228% nach NBC-Empfehlung und noch nicht müde!
„Tick, Tick, Boom! +120% sind erst der Anfang...“, hieß es von uns zu Jahresbeginn. Wie erwartet eilt die Aktie des…
Thinking about buying stock in Evolus, Rite Aid, Roku, Marathon Patent Group, or Otonomy?
NEW YORK , Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOLS,…
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy (OTIC) Looks Good: Stock Adds 5% in Session
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge…
Otonomy (OTIC) Investor Presentation - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy issues update for Otividex and OTO-313
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the…
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy: Q3 Earnings Insights
Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results.
Quarterly Results
Earnings per share were up 33.33% over the…
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy completes enrollment in pivotal study of Otvidex in inner ear disorder
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy (OTIC) Investor Presentation - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately....…
Otonomy to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy (OTIC) Corporate Presentation - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy +5%; Q2 earnings indicates advancing product pipeline
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy, Inc. (OTIC) CEO David Weber on Q2 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the…
OTONOMY, INC.: 10-Q Report
10-Q...…
Otonomy EPS beats by $0.02, misses on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Conference call and webcast today at 5 p.m. ET...…
Otonomy up 7% on license pact with Kyorin for hearing loss program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss...…
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to…
Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge…
Otonomy prices stock offering at $3.25
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy readies equity offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy Announces Proposed Public Offering
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!
Starke Tinnitus-Daten schicken die Aktie von Otonomy (WKN: A119VZ) nachbörslich in die Höhe. Im No Brainer Club reißt die Erfolgsserie…
Otonomy reports positive data on tinnitus candidate and Otividex
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy Provides Update on OTIVIDEX® Program
Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during…
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy Provides Update on Clinical Trials and Development Programs
Conference call and webcast today at 4:30 p.m. ET...…
Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge…
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy to host webcast for pipeline program update
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy to Host Pipeline Program Update Conference Call and Webcast
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy Provides Business Update Related to COVID-19 Pandemic
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the…
Otonomy, Inc. 2019 Q4 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomys (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Otonomy (OTIC) Reports Q4 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 23.40% and -15.46%, respectively, for the quarter ended December 2019. Do the…
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET...…
Otonomy to Present at Two Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development…